Status:
SUSPENDED
Bilateral Occipital Nerve Field Stimulation for the Treatment of dtCCH
Lead Sponsor:
Man and Science, SA
Conditions:
Chronic Cluster Headache
Eligibility:
All Genders
18-70 years
Phase:
NA
Brief Summary
The purpose of this study is to assess the initial safety, tolerability, and effectiveness of the novel BliStim occipital nerve field stimulation therapy for the prevention of chronic cluster headache...
Eligibility Criteria
Inclusion
- ICHD-3 criteria for chronic cluster headache
- Documented history of CCH since at least 2 years
- Minimum mean attack frequency of 4 attacks per week
- Age range: 18-70 years
- Difficult-to-treat CCH with documented previous complete failure, insufficient efficacy, intolerance, or contra-indications to most preventive CH treatments among which are oral steroids or suboccipital infiltrations, verapamil, lithium carbonate and topiramate.
- No preventive CH treatment or stable preventive CH medication for ≥ 2 weeks before enrolment. Subject agrees not to change existing treatment during the whole duration of the trial.
- Subject written informed consent provided before enrolment
- Subject willing and capable of subjective evaluation and to fill in an electronic CH diary, to understand questionnaires, and to read, understand and sign the written informed consent form.
- Subject willing and able to comply with study-related requirements, procedures, and visits.
Exclusion
- Other significant neurological, psychiatric, or disabling diseases which in the opinion of the investigator may interfere with the study.
- History of epilepsy, current treatment of epilepsy
- Documented history of cerebrovascular accident (CVA)
- Subjects suffering from a substance use disorder, as defined by Diagnostic and Statistical Manual of Mental Disorders (DSM) criteria. Recreational use of cannabis is allowed.
- Subjects at high risk of suicide/suicidal ideation in the past one year assessed with the C-SSRS
- Having another active implanted device such as a cardiac pacemaker, a spinal cord, peripheral nerve, sphenopalatine ganglion, or deep brain hypothalamic stimulator, and/or a drug delivery pump, etc.
- Cranial botulinum toxin injections in the past 3 months before enrolment. Administration of the following treatments in the last month before enrolment: monoclonal antibodies blocking calcitonin gene-related peptide transmission, suboccipital infiltrations with steroids and/or local anaesthetics, oral steroids, radiofrequency procedure or infiltrations of the sphenopalatine ganglion, opioids WHO 3.
- Medication overuse headache (ICHD 3 8.2)
- Inability to fill out an electronic diary.
- Previous surgery or trauma involving the cervical spine or the occipital bone
- Coagulopathy or required anticoagulant medications that cannot be safely discontinued in the perioperative period.
- Concurrent participation in another clinical study
- Planned pregnancy, pregnancy, or breastfeeding.
Key Trial Info
Start Date :
October 19 2023
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
March 30 2025
Estimated Enrollment :
10 Patients enrolled
Trial Details
Trial ID
NCT06124534
Start Date
October 19 2023
End Date
March 30 2025
Last Update
June 26 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
VITAZ Hospital
Sint-Niklaas, Belgium